References
1 New address: 5655 Greenshade Rd, San Diego, CA 92121, USA. Email: sakthi123@earthlink.net.
2a
Welch T.
Eswarakrishnan S.
Fluorine in Bioorganic Chemistry
Wiley-Interscience;
New York:
1991. and references cited therein
2b
Mikami K.
Itoh Y.
Yamanaka M.
Chem. Rev.
2004,
104:
1
3a
Park BK.
Kitteringham NR.
O’Neill PM.
Annu. Rev. Pharmacol. Toxicol.
2001,
41:
443
3b
Man H.
Corral LG.
Stirrling DI.
Muller GW.
Bioorg. Med. Chem. Lett.
2003,
13:
3415
4a FDA-Approved drugs based upon fluorinated nucleosides include 5F-3TC (AIDS) and Gemcitabine(cancer).
4b
Eldrup AB.
Prhavc M.
Brooks J.
Bhat B.
Prakash TP.
Song Q.
Bera S.
Bhat N.
Dande P.
Cook PD.
Bennet CF.
Carrol SS.
Ball RG.
Bosserman M.
Burlein C.
Colwell LF.
Fay JF.
Flores OA.
Getty K.
LaFamina RL.
Leone J.
MacCoss M.
McMasters DR.
Tomassini JE.
Langen DV.
Wolanski B.
Olseon DB.
J. Med. Chem.
2004,
47:
5284
4c
Zhou W.
Gumina G.
Chong Y.
Wang J.
Schinazi RF.
Chu CK.
J. Med. Chem.
2004,
47:
3399
4d
Yang Y.-Y.
Meng W.-D.
Qing F.-L.
Org. Lett.
2004,
6:
4257
5a
Kool ET.
Acc. Chem. Res.
2002,
35:
936 ; and references cited therein
5b
Dai Q.
Piccirilli JA.
Org. Lett.
2003,
5:
807
5c
Lai JS.
Kool ET.
J. Am. Chem. Soc.
2004,
126:
3040
5d
Robins MJ.
MacCoss M.
Naik SR.
Ramani G.
J. Am. Chem. Soc.
1976,
98:
7381
5e
Blackburn GM.
Brown D.
Martin SJ.
Parratt MJ.
J. Chem. Soc., Perkin Trans. 1
1987,
181
6
Kawasaki AM.
Casper MD.
Freier SM.
Lesnik EA.
Zounes MC.
Cummins LL.
Gonzalez C.
Cook PD.
J. Med. Chem.
1993,
36:
831
7a
Layzer JM.
Mccaffrey AP.
Tanner AK.
Huang Z.
Kay MA.
Sullenger BA.
RNA
2004,
10:
766
7b
Allerson CR.
Sioufi N.
Jarres R.
Prakash TP.
Naik N.
Berdeja A.
Wanders L.
Griffey RH.
Swayze EE.
Bhat B.
J. Med. Chem.
2005,
48:
901
8a
Cook PD.
Allen LB.
Streeter DG.
Huffman JH.
Sidwell RW.
Robins RK.
J. Med. Chem.
1978,
21:
1212
8b
Allen LB.
Huffman JH.
Cook PD.
Meyer RB.
Robins RK.
Sidwell RW.
Antimicrob. Agents Chemother.
1977,
12:
114
8c
Saunder PP.
Chao LY.
Loo TL.
Robins RK.
Biochem. Pharmacol.
1981,
30:
2374
8d
Revangar GR.
Gupta PK.
Adams AD.
Dalley NK.
McKernana PA.
Cook PD.
Canonico PG.
Robins RK.
J. Med. Chem.
1984,
27:
1389
9
Kumar A.
Khan SI.
Manglani A.
Khan ZK.
Katti SB.
Nucleosides Nucleotides
1994,
13:
1049 ; and references cited therein
10a
Eldrup AB.
Allerson CR.
Bennet CF.
Bera S.
Bhat B.
Bosserman M.
Brooks J.
Burlein C.
Carrol SS.
Cook PD.
Getty KL.
MacCoss M.
McMasters DR.
Olseon DB.
Prakash TP.
Prhavc M.
Song Q.
Tomassini JE.
Xia J.
J. Med. Chem.
2004,
47:
2283
10b
Shim J.
Larson G.
Lai V.
Naim S.
Wu JZ.
Antiviral Res.
2003,
58:
243
10c Ismaili H, Moulay A, Cheng Y, Lavalle J, Siddiqui A, and Storrer R. inventors; Intl. Patent. Appl. WO 01/60315.
10d Sommadossi JP, and Lacolla P. inventors; Intl. Patent Appl. WO 01/92282.
11
Minakawa N.
Kojima N.
Matsuda A.
J. Org. Chem.
1999,
64:
7158
12 However, synthesis and biological properties of 2,3-difluoro-3-deaza-Ad, 3-F-3-deaza-Ad, 3-Br-3-deaza-G and 3-Cl-3-deaza-G were reported. See: Liu MC.
Luo MZ.
Mozdziesz DE.
Lin TS.
Dutschman GE.
Gullen EA.
Cheng YC.
Sartorelli AC.
Nucleosides, Nucleotides Nucleic Acids
2001,
20:
1975
13
Minakawa N.
Sasabuchi Y.
Kiyosue A.
Kojima N.
Matsuda A.
Chem. Pharm. Bull.
1996,
44:
288
14
Robins RK.
Horner JK.
Greco CV.
Noell CW.
Beames CG.
J. Org. Chem.
1963,
28:
3041
15a
Cook PD.
Rousseau RJ.
Mian AM.
Meyer RB.
Dea P.
Ivanovics G.
Streeter DG.
Witkowski JT.
Stout MG.
Simon LN.
Sidwell RW.
Robins RK.
J. Am. Chem. Soc.
1975,
97:
2916
15b Carrol SS, LaFemina RL, Hall DL, Himmelberger AL, Kuo LC, MacCoss M, Olseon DB, Rutkowski CA, Tomassini JE, An H, Bhat B, Bhat N, Cook PD, Eldrup AB, Guinosso CJ, Prhavc M, and Prakash TP. inventors; Intl. Patent. Appl. WO 02/057425.
16a
Harry-O’kuru RE.
Smith JM.
Wolfe MS.
J. Org. Chem.
1997,
62:
1754
16b
Franchetti P.
Cappellacci L.
Marchetti S.
Trincavelli L.
Martini C.
Mazzoni MR.
Lucacchini A.
Grifantini M.
J. Med. Chem.
1998,
41:
1708
17
Niedballa U.
Vorbrüggen HJ.
J. Org. Chem.
1974,
39:
3654
18
Acevedo OL.
Andrews RS.
Cook PD.
Nucleosides Nucleotides
1993,
12:
403
19 Compound 5a (diastereomers 1:1): 1H NMR (300 MHz, CDCl3): δ = 3.92 (s, 3 H, OCH3), 4.66-4.90 (m, 3 H, 4′, 5′,5′′-H), 5.90-6.06 (m, 2 H, 2′,3′-H), 6.48 (d, J = 6.7 Hz, 1 H, 1′-H), 7.31-7.63 (m, 10 H, 9 Ar-H, Imi-2-H), 7.92-8.14 (m, 7 H, 6 × Ar-H, CHFCN). 19F NMR (282 MHz, CDCl3): δ (diastreomers) = -175.76 (d, J
F-H = 43.6 Hz), -172.72 (d, J
F-H = 43.6 Hz). HRMS: m/z calcd for C33H26FN3O9 [MNa+]: 650.1551; found: 650.1550. ESI-MS: m/z = 650 [MNa+].
Compound 5b (diastereomers 1:1): 1H NMR (300 MHz, CDCl3): δ = 2.15 (s, 3 H, COCH3), 2.20-2.50 (m, 5 H, 3′,3′′-H, Tol-CH3), 3.94 (s, 3 H, OCH3), 4.53-4.75 (m, 3 H, 4′, 5′,5′′-H), 5.40-5.46 (m, 1 H, 2′-H), 6.13-6.16 (m, 1 H, 1′-H), 7.25 (m, 2 H, Ar-H), 7.41 (d, 1 H, J = 43.1 Hz, CHFCN), 7.86-7.98 (m, 3 H, 2 × Ar-H, Imi-2-H). 19F NMR (282 MHz, CDCl3): δ (diastreomers) = -176.41 (d, J
F-H = 43.6 Hz),
-174.03 (d, J
F-H = 43.6 Hz). HRMS: m/z calcd for C22H22FN3O7 [MNa+]: 482.1334; found: 482.1333. ESI-MS: m/z = 482 [MNa+].
Compound 5c (diastereomers 1:1): 1H NMR (300 MHz, CDCl3): δ = 1.58 (2 × s, 3 H, CH3), 3.98 (2 × s, 3 H, OCH3), 4.78-4.96 (m, 3 H, 4′, 5′,5′′-H), 5.75 (2 × d, 1 H, 3′-H), 6.66 and 6.80 (2 × s, 1 H, 1′-H), 7.26-7.62 (m, 10 H, 9 × Ar-H, Imi-2-H), 7.80-8.19 and 8.20 (m, 7 H, 6 × Ar-H, CHFCN). 19F NMR (282 MHz, CDCl3): δ (diastereomers) = -179.31 (d, J
F-H = 41.6 Hz), -170.0 (d, J
F-H = 41.6 Hz). HRMS: m/z calcd for C34H28FN3O9 [MNa+]: 664.1707; found: 664.1704. ESI-MS: m/z = 664 [MNa+].
20a
Cook PD.
Rousseau RJ.
Mian AM.
Dea P.
Meyar RB.
Robins RK.
J. Am. Chem. Soc.
1976,
98:
1492
20b
Tanaka H.
Hirayama M.
Suzuki M.
Miyasaka T.
Matsuda A.
Ueda T.
Tetrahedron
1986,
42:
1971
21a
Cook PD.
Robins RK.
J. Org. Chem.
1978,
43:
289
21b
Revankar GR.
Gupta PK.
Adams AD.
Dalley NK.
McKernana PA.
Cook PD.
Canonico PG.
Robins RK.
J. Med. Chem.
1984,
27:
1389
22 Compound 12a (diastereomers 1:3): 1H NMR (300 MHz, DMSO-d
6): δ = 3.45-3.70 (m, 5 H, 2′, 3′-H, OCH3), 3.85-3.86 (m, 1 H, 4′-H), 4.04-4.16 (m, 2 H, 5′,5′′-H), 5.08-5.22 (m, 2 H, 3′, 5′′-OH), 5.40 and 5.49 (2 × d, J = 4.1, 4.7 Hz, 1 H, 2′-OH), 5.51 (d, J = 5.56 Hz, 1 H, 1′-H), 7.17 (d, J
H-F = 44.8 Hz, 0.3 H, CHF), 7.22 (d, J
H-F = 44.8 Hz, 0.7 H, CHF), 7.40 and 7.60 (2 × br s, 2 H, NH2), 8.21 and 8.24 (2 × br s, 1 H, Imi-2H), 8.50 (br s, 1 H, NH). 19F NMR (282 MHz, CDCl3): δ (diastereomers) = -176.84 (d, J
F-H = 43.6 Hz),
-173.84 (d, J
F-H = 43.6 Hz). HRMS: m/z calcd for C12H17FN4O6 [MNa+] = 355.1030; found: 355.1034. ESI-MS: m/z = 355 [MNa+].
23 To our surprise, 5-imidomethoxy imidazole-4-carboxamide riboside analogues similar to 12a have never been detected, or proposed to form, during the cyclization reactions of 4a or 10a in basic alcoholic solutions. See ref. 11 and ref. 20.
24 A similar ring-closure was also effected successfully when using 5% Na2CO3 in EtOH, but, because of its high polarity, we had difficulties in isolating the product from the inorganic salt. Although the ring-closure reaction could also be realized using several organic amine bases (DBU, pyridine, N,N-diisopropylethylamine, etc.), we prefer to use less volatile Et3N base.
25 Although the conversions of the ring-closure reactions were >80%, the high polarities of products 3a-c restricted their isolated yields to only 60-68%.
26 Compound 3b: UV (0.5 N NaOH): λmax = 287 nm (ε 9400). 1H NMR (300 MHz, DMSO-d
6): δ = 1.80-1.88 (m, 1 H, 3′-H), 2.08-2.18 (m, 1 H, 3′′-H), 3.51-3.55 (m, 1 H, 5′-H), 3.64-3.67 (m, 1 H, 5′′-H), 4.28-4.42 (m, 2 H, 4′-H, 2′-OH), 5.01 (t, 1 H, J = 5.3 Hz, 5′-OH), 5.52 (br s, 2 H, NH2), 5.61 (d, J = 4.4 Hz, 1 H, 2′-H), 5.78 (s, 1 H, 1′-H), 8.04 (s, 1 H, 2-H), 10.44 (br s, 1 H, NH). 19F NMR (282 MHz, DMSO-d
6): δ = -186.70. 13C NMR (75 MHz, DMSO-d
6): δ = 34.6, 62.9, 76.4, 81.7, 93.1 (d, J = 5.5 Hz), 122.2 (d, J = 215.0 Hz), 123.2, 132.1 (d, J = 9.0 Hz), 135.9 (d, J = 22.0 Hz), 137.6, 155.0. HRMS: m/z calcd for C11H14FN4O4 [MH+] = 285.0999; found: 285.0991; [MNa+]: 307.0819; found: 307.0809. ESI-MS: m/z = 285 [MH+].
Compound 3c: UV (H2O): λmax = 272 nm (ε 8200), 310 nm (ε 7100). 1H NMR (300 MHz, DMSO-d
6): δ = 0.71 (s, 3 H, CH3), 3.62-3.69 (m, 1 H, 5′-H), 3.82-3.93 (m, 3 H, 3′,4′,5′′-H), 5.15 (s, 1 H, 2′-OH), 5.21-5.27 (m, 2 H, 3′,5′-OH), 5.54 (br s, 2 H, NH2), 5.77 (s, 1 H, 1′-H), 8.24 (s, 1 H, 2-H), 10.46 (br s, 1 H, NH). 19F NMR (282 MHz, DMSO-d
6): δ =
-186.46. 13C NMR (75 MHz, DMSO-d
6): δ = 20.5, 59.7, 71.7, 79.5, 83.0, 93.3 (d, J = 7 Hz), 122.2 (d, J = 214 Hz), 122.9, 132.2 (d, J = 9 Hz), 135.9 (d, J = 22 Hz), 137.5, 155.0. HRMS: m/z calcd for C12H16FN4O5 [MH+]: 315.1105; found: 315.1102; [MNa+]: 337.0924; found: 337.0920. ESI-MS: m/z = 315 [MH+].
